Elevation of the thromboxane A2/prostacyclin ratio in urine of diabetic mice analyzed by gas chromatography/selected ion monitoring

Prostaglandins and Other Lipid Mediators

Volumn 55, Issue 2-3, 1998, Pages 83-93

  Hishinuma, Takanori ^a   Koseki, Yuko ^a   Murai, Yuriko ^a   Kotake, J ^c   Ishii, Fumio ^c   Suzuki, Ken Ichi ^b   Mizugaki, Michinao ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b Tohokukoseinenkin Hospital   (Japan)

^c NONE

Author keywords

Diabetes mellitus; GC; MS; Prostacyclin; Prostaglandin; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PROSTACYCLIN; STREPTOZOCIN; THROMBOXANE A2; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING DISORDER; BODY WEIGHT; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; INSULIN BLOOD LEVEL; ION MONITORING; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROSTAGLANDIN METABOLISM; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; URINE LEVEL;

EID: 0031998999     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(98)00012-4     Document Type: Article

References (31)

1. Smith W.L. The eicosanoids and their biochemical mechanisms of action. Biochem. J. 259:1989;315-324.
2. Baker R.R. The eicosanoids A historical overview . Clin. Biochem. 23:1990;455-458.
3. Needleman P., Raz A., Minkes M.S., Ferrendelli J.A., Sprecher H. Triene prostaglandins Prostacyclin and thromboxane biosynthesis and unique biological properties . Proc. Natl. Acad. Sci. USA. 76:1979;944-948.
4. 2 balance Pathophysiological and therapeutic implications . Br. Med. Bull. 39:1983;271-276.
5. Lagarde M., Gualde N., Rigaud M. Metabolic interactions between eicosanoids in blood and vascular cells. Biochem. J. 257:1989;313-320.
6. Halushka P.V., Dollery C.T., MacDermot J. Thromboxane and prostacyclin in disease A review . Q. J. Med. 52:1983;461-470.
7. Gerritsen M.E. Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc. Res. 32:1996;720-732.
8. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. ii:1978;117-119.
9. Tomasi V., Strano A., Orlandi M., Bartolini G., Davi G., Monti D., Taddeo U., Zavagli G. Are the vascular complications of diabetes mellitus preceded by an altered thromboxane/prostacyclin plasmatic ratio? Med. Hypotheses. 19:1986;229-241.
10. DeRubertis F. R., Craven P.A. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am. J. Kidney Dis. 22:1993;727-735.
11. Watanabe J., Sako Y., Umeda F., Nawata H. Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients. Diabetes Res. Clin. Pract. 22:1993;53-59.
12. Moreno A., De La Cruz J.P., Garcia Campos J., Sanchez De La Cuesta F. Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can. J. Ophthalmol. 30:1995;117-123.
13. Hisinuma T., Yu G.S.P., Takabatake M., Nakagawa Y., Ito K., Nishikawa M., Ishibashi M., Suzuki K., Matsumoto M., Toyoda T., Mizugaki M. Analysis of the thromboxane/prostacyclin balance in human urine by gas chromatography/selected ion monitoring abnormalities in diabetics . Prostaglandins Leukot. Essent. Fatty Acids. 54:1996;445-449.
14. 1α in human urine using gas chromatography/high resolution-selected ion monitoring. J. Chromatogr. 658:1994;11-19.
15. 2 in human urine improved by use of gas chromatography/high-resolution selected ion monitoring with 18O2-labelled analog as an internal standard. Biol. Mass Spectrom. 23:1994;612-620.
16. Rakieten N., Rakieten M.L., Nadkarni M.V. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother. Rep. 29:1963;91-98.
17. Hummel K.P., Dickie M.M., Coleman D.L. Diabetes, a new mutation in the mouse. Science. 153:1966;1127-1128.
18. Chick W.L., Like A.A. Studies in the diabetic mutant mouse III. Physiological factors associated with alterations in beta cell proliferation . Diabetologia. 6:1970;243-251.
19. Coleman D.L., Hummel K.P. Studies with the mutation, diabetes, in the mouse. Diabetologia. 3:1967;238-248.
20. Coleman D.L., Hummel K.P. Hyperinsulinemia in pre-weaning diabetes (db) mice. Diabetologia. 10:1974;607-610.
21. Cohen M.P., Clements R.S., Hud E., Cohen J.A., Ziyadeh F.N. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp. Nephrol. 4:1996;166-171.
22. Harrison H.E., Reece A.H., Johnson M. Effect of insulin treatment on prostacyclin in experimental diabetes. Diabetologia. 18:1980;65-68.
23. Johnson M., Harrison H.E., Raftery A.T., Elder J.B. Vascular prostacyclin may be reduced in man. Lancet. i:1979;325-326.
24. Silberbauer K., Schernthaner G., Sinzinger H., Piza-Katzer H., Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. N. Engl. J. Med. 300:1979;366-367.
25. Lane L.S., Jansen P.D., Lahav M., Rudy C. Circulating prostacyclin and thromboxane levels in patients with diabetic retinopathy. Ophthalmology. 89:1982;763-766.
26. Rösen P., Schrör K. Increased prostacyclin release from perfused hearts of acutely diabetic rats. Diabetologia. 18:1980;391-394.
27. Ylikorkala O., Kaila J., Viinikka L. Prostacyclin and thromboxane in diabetes. Br. Med. J. 283:1981;1148-1150.
28. Davis T.M.E., Mitchell M.D., Turner R.C. Prostacyclin and thromboxane metabolites in diabetes. Lancet. ii:1979;789-790.
29. 1α concentrations, and diabetic retinopathy. Br. Med. J. 282:1981;1259-1262.
30. Dollery C.T., Friedman L.A., Hensby C.N., Kohner E., Lewis P.J., Porta M., Webster J. Circulating prostacyclin may be reduced in diabetes. Lancet. ii:1979;1365.
31. Hirsh P.D., Campbell W.B., Willerson J.T., Hillis L.D. Prostaglandins and ischemic heart disease. Am. J. Med. 71:1981;1009-1026.